Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sitagliptin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 20/20 | 1.00 |
| ▸ | DPP8 | Q6V1X1 | 12/20 | 1.00 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.98 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.98 |
| ▸ | ACE | P12821 | 1/20 | 0.98 |
| ▸ | HTR2A | P28223 | 1/20 | 0.98 |
| ▸ | FAP | Q12884 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sitagliptin SCHEMBL572135 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL18131636 | 0.99 | DPP4 (0.98) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL31382815 | 0.99 | DPP4 (0.98) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL31513245 | 0.99 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL174489 | 0.99 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL29365085 | 0.99 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL1289311 | 0.99 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL19520418 | 0.99 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL17783 | 0.99 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL29421658 | 0.99 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016162877-A1 | \"A PROCESS FOR PREPARING 7-[(3R)-3-AMINO-L-OXO-4-(2,4,5TRIFLUOROPHENYL)BUTYI]- 5,6,7,8-TETRAHYDRO-3-(TRIFLUOROMETHYL)-L,2,4-TRIAZOLO[4,3-A]PYRAZINE HYDROCHLORIDE MONOHYDRATE AND ITS CRYSTALLINE FORM\ | HARMAN FINOCHEM LIMITED (IN) | 2016-10-13 | — | — | WO | claimed |
| US-20140051856-A1 | NOVEL SALTS OF DPP-IV INHIBITOR | CADILA HEALTHCARE LIMITED (IN) | 2014-02-20 | — | — | US | claimed |
| EP-2681220-A2 | NOVEL SALTS OF DPP-IV INHIBITOR | Cadila Healthcare Limited (IN) | 2014-01-08 | — | — | EP | claimed |
| WO-2012147092-A2 | NOVEL SALTS OF DPP-IV INHIBITOR | CADILA HEALTHCARE LIMITED (IN) | 2012-11-01 | — | — | WO | claimed |
| EP-4469459-B1 | PROCESS FOR PREPARING CRYSTALLINE SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE | ZAKL FARMACEUTYCZNE POLPHARMA S A (PL) | 2026-01-21 | — | — | EP | disclosed |
| WO-2025046479-A1 | A NOVEL POLYMORPH OF SITAGLIPTIN HYDROCHLORIDE AND PROCESS FOR ITS PREPARATION THEREOF | HIKAL LIMITED (IN) | 2025-03-06 | — | — | WO | disclosed |
| WO-2025046479-A1 | A NOVEL POLYMORPH OF SITAGLIPTIN HYDROCHLORIDE AND PROCESS FOR ITS PREPARATION THEREOF | HIKAL LIMITED (IN) | 2025-03-06 | — | — | WO | disclosed |
| EP-4469459-A1 | PROCESS FOR PREPARING CRYSTALLINE SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE | Zaklady Farmaceutyczne Polpharma S.A. (PL) | 2024-12-04 | — | — | EP | disclosed |
| EP-4469459-A1 | PROCESS FOR PREPARING CRYSTALLINE SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE | Zaklady Farmaceutyczne Polpharma S.A. (PL) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023139276-A1 | PROCESS FOR PREPARING CRYSTALLINE SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE | ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. (PL) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023139276-A1 | PROCESS FOR PREPARING CRYSTALLINE SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE | ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. (PL) | 2023-07-27 | — | — | WO | disclosed |
| WO-2022074664-A1 | AN IMMEDIATE RELEASE COMPOSITION OF SITAGLIPTIN HYDROCHLORIDE | V-ENSURE PHARMA TECHNOLOGIES PRIVATE LIMITED (IN) | 2022-04-14 | — | — | WO | disclosed |
| US-20140051856-A1 | NOVEL SALTS OF DPP-IV INHIBITOR | CADILA HEALTHCARE LIMITED (IN) | 2014-02-20 | — | — | US | disclosed |
| US-20140051856-A1 | NOVEL SALTS OF DPP-IV INHIBITOR | CADILA HEALTHCARE LIMITED (IN) | 2014-02-20 | — | — | US | disclosed |
| EP-2681220-A2 | NOVEL SALTS OF DPP-IV INHIBITOR | Cadila Healthcare Limited (IN) | 2014-01-08 | — | — | EP | disclosed |
| WO-2012147092-A2 | NOVEL SALTS OF DPP-IV INHIBITOR | CADILA HEALTHCARE LIMITED (IN) | 2012-11-01 | — | — | WO | disclosed |
| US-8278486-B2 | Process and intermediates for the preparation of N-acylated-4-aryl beta-amino acid derivatives | CHIRAL QUEST, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| EP-2470542-A2 | PREPARATION OF SITAGLIPTIN AND SALTS THEREOF | Dr. Reddy's Laboratories Ltd. (IN) | 2012-07-04 | — | — | EP | disclosed |
| WO-2011025932-A2 | PREPARATION OF SITAGLIPTIN AND SALTS THEREOF | DR. REDDY'S LABORATORIES LTD. (IN) | 2011-03-03 | — | — | WO | disclosed |
| US-20100280245-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF N-ACYLATED-4-ARYL BETA-AMINO ACID DERIVATIVES | CHIRAL QUEST, INC. | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051856-A1 | NOVEL SALTS OF DPP-IV INHIBITOR | DPP4, DPP3, DPP9 | DPP4 1/4885DPP8 4/4885DPP9 3/4885 |
| US-20100280245-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF N-ACYLATED-4-ARYL BETA-AMINO ACID DERIVATIVES | NR4A3, GRIA3, NR2C2 | DPP4 3380/4885DPP8 3630/4885DPP9 4560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.